Afsaneh Barzi, MD, PhD, City of Hope

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.

Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.